BACKGROUND
Ambulating medical inpatients may improve outcomes, but this practice is often overlooked by nurses who have competing clinical duties.
OBJECTIVE
This study aimed to assess the feasibility and effectiveness of dedicated mobility technician‐assisted ambulation in older inpatients.
DESIGN
This study was a single‐blind randomized controlled trial.
SETTING
Patients aged ≥60 years and admitted as medical inpatients to a tertiary care center were recruited.
INTERVENTION
Patients were randomized into two groups to participate in the ambulation protocol administered by a dedicated mobility technician. Usual care patients were not seen by the mobility technician but were not otherwise restricted in their opportunity to ambulate.
MEASUREMENTS
Primary outcomes were length of stay and discharge disposition. Secondary outcomes included change in mobility measured by six‐clicks score, daily steps measured by Fitbit, and 30‐day readmission.
RESULTS
Control (n = 52) and intervention (n = 50) groups were not significantly different at baseline. Of patients randomized to the intervention group, 74% participated at least once. Although the intervention did not affect the primary outcomes, the intervention group took nearly 50% more steps than the control group (P = .04). In the per protocol analysis, the six‐clicks score significantly increased (P = .04). Patients achieving ≥400 steps were more likely to go home (71% vs 46%, P = .01).
CONCLUSIONS
Attempted ambulation three times daily overseen by a dedicated mobility technician was feasible and increased the number of steps taken. A threshold of 400 steps was predictive of home discharge. Further studies are needed to establish the appropriate step goal and the effect of assisted ambulation on hospital outcomes.
The awareness, diagnosis and management of chronic oedema and lymphoedema is improving. The enduring treatment format for the condition has always been regarded as the 'four cornerstones' of care for maintenance therapy in the UK. However, with changes in technology, availability of additional treatments and increased research and studies, this baseline is changing. This article outlines some of the recent changes and advancement in diagnostic tools and new technologies used in diagnosing and managing lymphoedema and chronic oedema. Emerging therapies will be introduced, as will other aspects of care that may now be considered 'essential care' in the management of lymphoedema and chronic oedema.
KEY WOrDsw Lymphoedema w Essential care w Advanced assessment
The purpose of this article is to discuss the use of custom made compression garments in the management of lymphoedema and chronic oedema. Patients often present to therapists with inappropriate, ill-fitting garments that can contribute to an increase in oedema and poor limb shape. Patients frequently report garments as being uncomfortable and therefore intolerable leading to a lack of concordance with wearing garments. The selection and fitting of the correct garment can affect outcomes and the patients' quality of life. The focus of this article is to increase the health professionals' knowledge and skills in the selection, measurement and fitting of custom made garments to ensure correct fit and increased concordance when compression garments are prescribed. KEY WORDS Chronic oedema w lymphoedema w flat knit compression garments w static stiffness
The MCID ranged from 3.3 to 5.1 for the AM-PAC basic mobility version and 3.5 to 4 for the adapted version, with the MDC as the lower limit. Changes in the AM-PAC for people with low back pain may be interpreted using the estimated MCID. Future studies are needed to determine the AM-PAC MCID for populations other than those with low back pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.